UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prolonged treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing

Gynecologic oncology reports, 2024-08, Vol.54, p.101458, Article 101458

Rose, Peter G.

2024

Volltextzugriff (PDF)

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Journal of clinical oncology, 2019-06, Vol.37 (16), p.1380-1390

2019

Volltextzugriff (PDF)

Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy

Journal of clinical oncology, 2015-07, Vol.33 (19), p.2136-2142

2015

Volltextzugriff (PDF)

Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report

Gynecologic oncology reports, 2023-12, Vol.50, p.101311, Article 101311

Rose, Peter G

2023

Volltextzugriff (PDF)

Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective

Cancer drug resistance, 2022-01, Vol.5 (2), p.415-423

Rose, Peter G.

2022

Volltextzugriff (PDF)

Role of Surgery in Ovarian Carcinoma

Journal of clinical oncology, 2007-07, Vol.25 (20), p.2873-2883

2007

Volltextzugriff (PDF)

Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2007-08, Vol.25 (24), p.3621-3627

2007

Volltextzugriff (PDF)

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2011-06, Vol.29 (16), p.2259-2265

2011

Volltextzugriff (PDF)

Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2008-01, Vol.26 (1), p.83-89

2008

Volltextzugriff (PDF)

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial

Gynecologic oncology, 2008-06, Vol.109 (3), p.329-334

2008

Volltextzugriff (PDF)

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)

Gynecologic oncology, 2018-08, Vol.150 (2), p.247-252

2018

Volltextzugriff (PDF)

Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic Oncology Group trials of cisplatin-based chemoradiation

Gynecologic oncology, 2014-11, Vol.135 (2), p.208-212

2014

Volltextzugriff (PDF)

Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center

Gynecologic oncology, 2013-07, Vol.130 (1), p.121-126

2013

Volltextzugriff (PDF)

Fertility-Sparing Surgery for Early-Stage Cervical Cancer: A Systematic Review of the Literature

Journal of minimally invasive gynecology, 2021-03, Vol.28 (3), p.513-526.e1

2021

Volltextzugriff (PDF)

Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2010-06, Vol.28 (16), p.2727-2731

2010

Volltextzugriff (PDF)

Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer

The oncologist (Dayton, Ohio), 2005-03, Vol.10 (3), p.205-214

Rose, Peter G.

2005

Volltextzugriff (PDF)

A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)

Gynecologic oncology, 2015-02, Vol.136 (2), p.240-245

2015

Volltextzugriff (PDF)

Long-Term Follow-Up of a Randomized Trial Comparing Concurrent Single Agent Cisplatin, Cisplatin-Based Combination Chemotherapy, or Hydroxyurea During Pelvic Irradiation for Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study

Journal of clinical oncology, 2007-07, Vol.25 (19), p.2804-2810

2007

Volltextzugriff (PDF)

Are the differences in treatment outcome for adenocarcinoma of the cervix different enough to change the treatment paradigm?

Gynecologic oncology, 2012-05, Vol.125 (2), p.285-286

Rose, Peter G

2012

Volltextzugriff (PDF)

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

Gynecologic oncology, 2008-06, Vol.109 (3), p.323-328

2008

Volltextzugriff (PDF)

High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition

NPJ precision oncology, 2021-12, Vol.5 (1), p.101-11, Article 101

2021

Volltextzugriff (PDF)

Symptoms of Women With High-Risk Early-Stage Ovarian Cancer

Obstetrics and gynecology (New York. 1953), 2022-06, Vol.139 (6), p.1196-1196

Rose, Peter G.

2022

Volltextzugriff (PDF)

Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes

International journal of gynecological cancer, 2019-09, Vol.29 (7), p.1126-1133

2019

Volltextzugriff (PDF)

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

Gynecologic oncology, 2012-11, Vol.127 (2), p.345-350

2012

Volltextzugriff (PDF)

LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer

Journal of ovarian research, 2023-06, Vol.16 (1), p.122-19, Article 122

2023

Volltextzugriff (PDF)

1 – 25 von 1.708

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.413)
Mit Volltextzugriff
(1.301)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(918)
IngentaConnect Journals
(709)
Journals@Ovid
(642)
EZB Free E-Journals
(637)
Publisher or Other Site
(378)
Elsevier ScienceDirect Journals Complete
(343)
IngentaConnect Journals
(302)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(251)
Wiley Online Library All Journals
(223)
Ebook Central Perpetual and DDA
(205)
eBooks on EBSCOhost
(204)
Wiley Online Library All Obooks
(167)
Wiley Online Library Full Collection 2018
(145)
SpringerLink
(87)
JSTOR Complete Journals
(84)
Nature
(74)
Oxford journals
(70)
Taylor & Francis
(67)
Taylor & Francis:Master (3349 titles)
(58)
Oxford Journals 2020 Medicine
(58)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

Prolonged treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy

Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report

Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective

Role of Surgery in Ovarian Carcinoma

Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)

Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic Oncology Group trials of cisplatin-based chemoradiation

Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center

Fertility-Sparing Surgery for Early-Stage Cervical Cancer: A Systematic Review of the Literature

Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study

Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer

A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)

Long-Term Follow-Up of a Randomized Trial Comparing Concurrent Single Agent Cisplatin, Cisplatin-Based Combination Chemotherapy, or Hydroxyurea During Pelvic Irradiation for Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study

Are the differences in treatment outcome for adenocarcinoma of the cervix different enough to change the treatment paradigm?

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition

Symptoms of Women With High-Risk Early-Stage Ovarian Cancer

Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer

Suchergebnisse filtern